This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Müller, V. Articles by Pantel, K. Search for Related Content PubMed PubMed Citation Articles by Müller, V. Articles by Pantel, K.

Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity

Authors' Affiliations: ¹ Institute of Tumor Biology, ² Clinic of Gynecology, ³ Institute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, and ⁴ Greiner Bio-One GmbH, Frickenhausen, Germany

Requests for reprints: Klaus Pantel, Institut für Tumorbiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany. Phone: 49-40-42803-3503; Fax: 49-40-42803-5379; E-mail: pantel{at}uke.uni-hamburg.de.

Purpose: The incidence and biological characteristics of circulating tumor cells in the blood of patients with breast cancer were examined and subgroups were evaluated in the context of systemic treatment and the presence of disseminated tumor cells in bone marrow.

Experimental Design: Circulating tumor cells were isolated from the peripheral blood of patients with breast cancer using a gradient system designed for the enrichment of circulating tumor cells (OncoQuick). Circulating tumor cells were identified with the anti-cytokeratin antibody, A45-B/B3. In subsets of patients, expression of the proliferation-associated Ki-67 antigen in circulating tumor cells and the concomitant presence of micrometastases in bone marrow were examined.

Results: In patients with primary breast cancer (stage M₀), circulating tumor cells were detected in 5 of 60 patients (8.3%) after surgery and before initiation of adjuvant chemotherapy; a positive correlation to the presence of disseminated tumor cells in bone marrow was observed (P = 0.030, n = 53). During the course of adjuvant chemotherapy, repeated analysis of 20 M₀ patients revealed the occurrence of circulating tumor cells in 7 of 16 patients that were initially negative. Patients with metastatic disease (stage M₁) showed circulating tumor cells in 25 of 63 cases (39.7%, P < 0.0001 as compared with M₀ patients), and a positive finding was correlated with elevated concentrations of the serum tumor marker CA15.3 (P = 0.0093). Performing repeated analysis in a subgroup of 25 M₁ patients, circulating tumor cells were found more frequently in patients with progressive disease than in patients with stable disease or remission (87.5% versus 43.8% of patients with circulating tumor cells, respectively; P = 0.047). Independent of the disease-stage, none of the 47 patients examined for the proliferative status of their circulating tumor cells showed coexpression of Ki-67.

Conclusions: Circulating tumor cells seem to be nonproliferating cells that persist during chemotherapy. Circulating tumor cell detection is linked to disease progression and elevated tumor marker concentrations in patients with metastatic breast cancer.

Key Words: Breast cancer • circulating tumor cells • disseminated tumor cells blood • micrometastases bone marrow • systemic therapy

This article has been cited by other articles:

				R. J. Jones, C. D. Gocke, Y. L. Kasamon, C. B. Miller, B. Perkins, J. P. Barber, M. S. Vala, J. M. Gerber, L. L. Gellert, M. Siedner, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma Blood, June 4, 2009; 113(23): 5920 - 5926. [Abstract] [Full Text] [PDF]

				N. Xenidis, M. Ignatiadis, S. Apostolaki, M. Perraki, K. Kalbakis, S. Agelaki, E. N. Stathopoulos, G. Chlouverakis, E. Lianidou, S. Kakolyris, et al. Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer J. Clin. Oncol., May 1, 2009; 27(13): 2177 - 2184. [Abstract] [Full Text] [PDF]

				P. WIMBERGER, M. HEUBNER, H. LINDHOFER, M. JAGER, R. KIMMIG, and S. KASIMIR-BAUER Influence of Catumaxomab on Tumor Cells in Bone Marrow and Blood in Ovarian Cancer Anticancer Res, May 1, 2009; 29(5): 1787 - 1791. [Abstract] [Full Text] [PDF]

				H. I. Scher and K. Pantel Bone Marrow Aspiration for Disseminated Tumor Cell Detection: A Must-Have Test or Is the Jury Still Out? J. Clin. Oncol., April 1, 2009; 27(10): 1531 - 1533. [Full Text] [PDF]

				J.-Y. Pierga, F.-C. Bidard, C. Mathiot, E. Brain, S. Delaloge, S. Giachetti, P. de Cremoux, R. Salmon, A. Vincent-Salomon, and M. Marty Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial Clin. Cancer Res., November 1, 2008; 14(21): 7004 - 7010. [Abstract] [Full Text] [PDF]

				C. Alix-Panabieres, S. Riethdorf, and K. Pantel Circulating Tumor Cells and Bone Marrow Micrometastasis Clin. Cancer Res., August 15, 2008; 14(16): 5013 - 5021. [Abstract] [Full Text] [PDF]

				H. Fiegl, A. Jones, C. Hauser-Kronberger, G. Hutarew, R. Reitsamer, R. L. Jones, M. Dowsett, E. Mueller-Holzner, G. Windbichler, G. Daxenbichler, et al. Methylated NEUROD1 Promoter is a Marker for Chemosensitivity in Breast Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3494 - 3502. [Abstract] [Full Text] [PDF]

				A Vincent-Salomon, F C Bidard, and J Y Pierga Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues J. Clin. Pathol., May 1, 2008; 61(5): 570 - 576. [Abstract] [Full Text] [PDF]

				K. Pantel, C. Alix-Panabieres, and S. Riethdorf Circulating Tumor Cells: Detection and Clinical Relevance Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 603 - 610. [Abstract] [Full Text] [PDF]

				K. Pachmann, O. Camara, A. Kavallaris, S. Krauspe, N. Malarski, M. Gajda, T. Kroll, C. Jorke, U. Hammer, A. Altendorf-Hofmann, et al. Monitoring the Response of Circulating Epithelial Tumor Cells to Adjuvant Chemotherapy in Breast Cancer Allows Detection of Patients at Risk of Early Relapse J. Clin. Oncol., March 10, 2008; 26(8): 1208 - 1215. [Abstract] [Full Text] [PDF]

				F.-C. Bidard, A. Vincent-Salomon, B. Sigal-Zafrani, V. Dieras, C. Mathiot, L. Mignot, J.-P. Thiery, X. Sastre-Garau, and J.-Y. Pierga Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells Ann. Onc., March 1, 2008; 19(3): 496 - 500. [Abstract] [Full Text] [PDF]

				W. He, H. Wang, L. C. Hartmann, J.-X. Cheng, and P. S. Low In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry PNAS, July 10, 2007; 104(28): 11760 - 11765. [Abstract] [Full Text] [PDF]

				S. Riethdorf, H. Fritsche, V. Muller, T. Rau, C. Schindlbeck, B. Rack, W. Janni, C. Coith, K. Beck, F. Janicke, et al. Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System Clin. Cancer Res., February 1, 2007; 13(3): 920 - 928. [Abstract] [Full Text] [PDF]

				M. Lacroix Significance, detection and markers of disseminated breast cancer cells Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067. [Abstract] [Full Text] [PDF]

				K. Pantel and U. Woelfle Circulating Tumor Cells as an Indicator of Invasion Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 116 - 119. [Full Text] [PDF]

				P. Wulfing, J. Borchard, H. Buerger, S. Heidl, K. S. Zanker, L. Kiesel, and B. Brandt HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients. Clin. Cancer Res., March 15, 2006; 12(6): 1715 - 1720. [Abstract] [Full Text] [PDF]